On markets and morals—(re-)establishing independent decision making in healthcare
Author:
- 20 January 2012
- journal article
- Published by Springer Nature in Medicine, Health Care and Philosophy
- Vol. 16 (2) , 311-315
Abstract
Medical practitioners owe much of the significant progress made in the diagnosis and treatment of disease to industrial research. Hence, co-operation between providers of medical services, most notably medical practitioners, and the pharmaceutical industry is in the best interest of patients. Yet, empirical evidence shows how well-directed influence exerted by the pharmaceutical industry impacts physicians’ decision-making. Profit-motivated inducement by the pharmaceutical industry may expose patients to considerable risks. Against what many think to be based on overwhelming evidence, Joao Calinas-Correia takes the view that the criticism levelled at the pharmaceutical industry as well as the call for transparency in the relationships between physicians and the industry are exaggerated. In his polemic he praises “Big Pharma” as a success and espouses the view that the undesired consequences of its activities are allegedly inherent in the underlying market environment shaped by politics. Moreover, he believes that the proposals made to control and eliminate such undesired effects will lead to mediocrity. Astonishingly, his polemic reaches out to contest the appropriateness of setting rules at all—even if being set by a democratic process. Calinas-Correia’s assertions are based on the wrong premises. They fail to recognize that today individual civil rights and liberties often enough do not have to be defended against encroachments by governmental authorities. Rather, it is incumbent on the state to create rules designed to defend the individual against infringements by overly powerful non-governmental institutions, in our case the medical-industrial complex. Given the power exercised by physicians and the special nature of their role in public health, clear-cut rules have to be enacted and implemented with respect to their relationship to Big Pharma.Keywords
This publication has 11 references indexed in Scilit:
- Change of Government: One More Big Bang Health Care Reform in England's National Health ServiceInternational Journal of Health Services, 2011
- The Haunting of Medical Journals: How Ghostwriting Sold “HRT”PLOS Medicine, 2010
- Who benefits from treating prehypertension?BMJ, 2010
- Disclosing Industry Relationships — Toward an Improved Federal Research PolicyNew England Journal of Medicine, 2010
- Fragmented Foundations2010
- The Anonymous Matrix: Human Rights Violations by 'Private' Transnational ActorsThe Modern Law Review, 2006
- The corporate coauthorJournal of General Internal Medicine, 2005
- Quantitative analysis of sponsorship bias in economic studies of antidepressantsThe British Journal of Psychiatry, 2003
- Selling sickness: the pharmaceutical industry and disease mongeringCommentary: Medicalisation of risk factorsBMJ, 2002
- Complimentary journeys to the World Congress of Gastroenterology - an inquiry of potential sponsors and beneficiariesZeitschrift für Gastroenterologie, 2000